CA2531850A1 - Method for measuring viral infectivity - Google Patents
Method for measuring viral infectivity Download PDFInfo
- Publication number
- CA2531850A1 CA2531850A1 CA002531850A CA2531850A CA2531850A1 CA 2531850 A1 CA2531850 A1 CA 2531850A1 CA 002531850 A CA002531850 A CA 002531850A CA 2531850 A CA2531850 A CA 2531850A CA 2531850 A1 CA2531850 A1 CA 2531850A1
- Authority
- CA
- Canada
- Prior art keywords
- virus
- cells
- antibody
- polypeptide
- viral
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims abstract description 38
- 230000003612 virological effect Effects 0.000 title claims abstract description 31
- 241000700605 Viruses Species 0.000 claims abstract description 61
- 239000002245 particle Substances 0.000 claims abstract description 44
- 208000015181 infectious disease Diseases 0.000 claims abstract description 40
- 230000002458 infectious effect Effects 0.000 claims abstract description 22
- 238000000684 flow cytometry Methods 0.000 claims abstract description 12
- 229920001184 polypeptide Polymers 0.000 claims description 27
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 27
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 27
- 108090000623 proteins and genes Proteins 0.000 claims description 11
- 108700008625 Reporter Genes Proteins 0.000 claims description 7
- 201000000582 Retinoblastoma Diseases 0.000 claims description 6
- 241000701161 unidentified adenovirus Species 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 4
- 230000010076 replication Effects 0.000 claims description 4
- 230000002950 deficient Effects 0.000 claims description 3
- 238000010166 immunofluorescence Methods 0.000 claims description 3
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical group CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 claims description 2
- 238000005259 measurement Methods 0.000 abstract description 5
- 238000004448 titration Methods 0.000 abstract description 3
- 210000004027 cell Anatomy 0.000 description 64
- 238000002360 preparation method Methods 0.000 description 17
- 238000003556 assay Methods 0.000 description 12
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 4
- 244000309466 calf Species 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 108700019146 Transgenes Proteins 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 230000002349 favourable effect Effects 0.000 description 3
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 239000013598 vector Substances 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- 241000701093 Suid alphaherpesvirus 1 Species 0.000 description 2
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 2
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 2
- 238000005571 anion exchange chromatography Methods 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000001493 electron microscopy Methods 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 238000012744 immunostaining Methods 0.000 description 2
- 159000000003 magnesium salts Chemical class 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 101710169336 5'-deoxyadenosine deaminase Proteins 0.000 description 1
- 102000055025 Adenosine deaminases Human genes 0.000 description 1
- 241000201370 Autographa californica nucleopolyhedrovirus Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 241000450599 DNA viruses Species 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 108010054218 Factor VIII Proteins 0.000 description 1
- 102000001690 Factor VIII Human genes 0.000 description 1
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 1
- 102000018997 Growth Hormone Human genes 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 101000746367 Homo sapiens Granulocyte colony-stimulating factor Proteins 0.000 description 1
- 241000701085 Human alphaherpesvirus 3 Species 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 102000003996 Interferon-beta Human genes 0.000 description 1
- 108090000467 Interferon-beta Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 1
- 241000125945 Protoparvovirus Species 0.000 description 1
- 241001068263 Replication competent viruses Species 0.000 description 1
- 206010051497 Rhinotracheitis Diseases 0.000 description 1
- 241000580858 Simian-Human immunodeficiency virus Species 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 241000710960 Sindbis virus Species 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 230000003263 anti-adenoviral effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000234 capsid Anatomy 0.000 description 1
- 101150055766 cat gene Proteins 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000002380 cytological effect Effects 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 229960000301 factor viii Drugs 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 229940044627 gamma-interferon Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 230000001524 infective effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000010212 intracellular staining Methods 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- UPSFMJHZUCSEHU-JYGUBCOQSA-N n-[(2s,3r,4r,5s,6r)-2-[(2r,3s,4r,5r,6s)-5-acetamido-4-hydroxy-2-(hydroxymethyl)-6-(4-methyl-2-oxochromen-7-yl)oxyoxan-3-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide Chemical compound CC(=O)N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@H](O)[C@@H](NC(C)=O)[C@H](OC=2C=C3OC(=O)C=C(C)C3=CC=2)O[C@@H]1CO UPSFMJHZUCSEHU-JYGUBCOQSA-N 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The instant invention addresses the need for a more accurate method of quantitating infectious viral particles in a population. The methods of the instant invention are based on the unexpected and surprising result that flow cytometry analysis of cells infected at a low ratio of particle number to cell number yields a more accurate measurement of infectious virus titer than traditional titration methods.
Description
s METI30D FOR MEASURING VIRAL INFECTIVITY
BACKGROUND OF TFiE INVENTION
A particular challenge in the delivery of a gene by a viral vector for therapeutic purposes is the preparation and accurate characterization of clinical dosage forms. Total particle measurement can be made by such techniques as electron microscopy of viral preparations or measurement of total DNA by optical density at 260 nm of a sodium dodecyl sulfate (SDS) treated virus suspension. However, infectivity of a viral preparation, i.e., the number of infectious viral particles in a preparation of virus, is more challenging to accurately measure.
Traditionally, infectivity particles are measured in culture by a plaque-forming unit assay (pfu) that scores the number of viral plaques as a function of dilution. An alternative to the pfu assay is the tissue culture infective dose procedure (TCIDSo), which estimates infectivity as a function of intracellular staining for an antigen by direct immunofluorescence. The methods suffer from limitations including a high degree of inter-assay variability and are affected by such factors as virus replication status, vector characteristics, and virus-cell interactions.
More recently, flow cytometry or FACS (fluorescence-activated cell sorter) assays have been used to measure the number of infected cells in cell cultures infected at relatively high multiplicities of infection. For example, Saalmuller and Mettenleiter (J. Virol. Methods 44:99-108 (1993)) disclose the identification and quantitation of cells infected by recombinant pseudorabies virus mutants by the reaction of intracellular ~i-galactosidase expressed during infection with recombinant viruses with a fluorogenic substrate, followed by detection of positive cells in flow cytometry. Morris et al. (Virolow 197(1):339-48 (1993)) studied the process of productive and non-productive recombinant AcMNPV infection in cultured cells by immunostaining cells to detect the reporter CAT gene product.
The instant invention addresses the need for a more accurate method of quantitating infectious viral particles in a population.
SUMMARY OF THE INVENTION
The methods of the instant invention are based on the unexpected and surprising result that flow cytometry analysis of cells infected at a low virus to cell ratio yields a more accurate measurement of infectious virus titer than traditional titration methods.
One aspect of the invention is a method for determining the number of infectious virus particles in a population of virus particles comprising:
i) infecting cells in a cell population at a total particle to cell ratio of less than about 100:1 to about 0.1:1 to generate infected cells;
ii) reacting a polypeptide expressed by the virus in infected cells with an antibody labeled with a fluorescent tag, the antibody having specificity for a polypeptide expressed by the virus; and iii) measuring immunofluorescence in the product of step (ii) by flow cytometry to determine the number of infected cells, thereby determining the number of infectious virus particles.
When the virus is a recombinant virus, the viral polypeptide can be encoded by an exogenous gene, such as a reporter gene. In some embodiments of the invention, the exogenous gene is a tumor suppressor gene such as p53 or , retinoblastoma (RB). The recombinant virus can be replication competent or defective, deficient or incompetent.
In some embodiments of the invention, the virus is adenovirus. Thus, when the infected cells are cultured after infection to allow expression of a viral polypeptide, the viral polypeptide can be an adenovirus polypeptide such as hexon.
Typically the viral polypeptide is reacted with at least one antibody, although the antibody can be a mixture of antibodies. The antibody can be polyclonal or monoclonal.
In preferred embodiments of the invention,~the total particle to cell ratio is less than about 100:1, typically less than about 10:1, preferably less than about 5:1, more preferably less than about 1:1. In some embodiments, the ratio can be as low as about 0.1:1.
DETAILED DESCRIPTION
' The instant invention provided methods for quantitating infectious viral particles in a population of virus particles. The term "infectious" as used herein is intended to refer to the ability of a virus to enter cells and direct the synthesis of at least one polypeptide encoded by the virus. The ability to reproduce the viral nucleic acid is not required, but is included, by this definition.
Typically, not every virus particle in a preparation is infectious. For example, particles can be damaged in preparation of the virus, thereby not affecting total particle number but decreasing the number of particles capable of infection. Furthermore, empty capsids or instability of the virus extracellularly can also contribute to the decrease in infectivity. The range of non-infectious particles to infectious particles in viral preparations can range from 1:1 to greater than 100:1. However, even non-infectious viruses can cause cytological changes or damage to exposed cells.
Thus, it is advantageous to have an accurate measure of the number of infectious particles in a population so as to minimize the number of non-infectious viral particles to which cells are exposed.
Virtually any virus can be quantitated, or titered, by the methods of the instant invention, including DNA
viruses, RNA viruses, replication competent viruses, replication incompetent viruses, recombinant viruses, viruses carrying transgenes, etc. Preferably, the virus can infect cells in culture. Some example of viruses amenable to this technique include, but are not limited to, adenovirus, adeno-associated virus, retrovirus, herpes simplex virus, parvovirus, Epstein Barr virus, rhinotracheitis virus, parainfluenza virus, bovine diarrhea virus, sindbis virus, baculovirus, pseudorabies virus, varicella-zoster virus, cytomegalovirus, HIV, hepatitis A, B, and C viruses, and vaccinia.
In some embodiments of the invention, infectivity is measured by antibodies directed against a polypeptide expressed by the virus. The polypeptide may be a structural viral polypeptide, a regulatory polypeptide, a polypeptide such as a polymerase, and so on. In some embodiments of the invention, the polypeptide is preferably expressed by an exogenous gene incorporated into the virus, such as a reporter gene. Some examples of reporter genes include (3-galactosidase and chloramphenicol transacetylase (CAT). In further embodiments of the invention, the reporter gene is detected by antibodies directed against a product of the action of the reporter gene, such as the action of an enzyme on a substrate.
In other embodiments of the invention, the exogenous gene is a transgene intended for therapeutic use. Some examples include but are not limited to tumor suppressor genes, including p53 or retinoblastoma (RB); interleukins, including IL-2, IL-4, and IL-10; interferons, including alpha-, beta-, and gamma interferon; other cytokines; thymidine kinase; growth factors, including GCSF and growth hormone; Factor VIII; adenosine deaminase, and so on. Typically production of polypeptide encoded by a transgene will be measured by an antibody directed against the polypeptide.
Antibodies used for detection can be polyclonal, , monoclonal, or include mixtures of such antibodies.
Typically, the detection is done directly by using a , fluorescein-conjugated antibody directed against the viral polypeptide. However, indirect assays are also possible, in which the antibody directed against the viral polypeptide is then reacted with a fluorescein-labeled antibody. Any fluorescent label compatible with flow cytometry can be used.
To perform the assay of the invention, typically, the total number of virus particles in a viral preparation is 5 first measured by any of a number of traditional techniques.
For example, an aliquot of a virus preparation can be prepared in a buffer containing 0.1% sodium dodecyl sulfate (SDS), after which the optical absorbance is measured at 260 nm (Maizel et al. yirologv 36:115-125 (1968)). Total particle counts can also be obtained by preparing a sample of the viral preparation for electron microscopy, and simply counting the number of particles. A further technique for particle enumeration can include the use of anion-exchange chromatography (Huyghe et al. Oman Gene erarw 6:1403-1416 (1995)).
Cells are then infected with dilutions of the viral preparations at total particle number to cell number ratios no higher than about 100:1, typically less than about 10:1, preferably less than about 5:1, more preferably less than about 1:1. In some embodiments the ratio is as low as about 0.1:1. Typically, at least one infection will be performed, although in some embodiments at least two parallel infections are performed at different particle to cell ratios. The cells used are typically known to be sensitive to infection by the virus. It is not required that the cells support replication by the virus, but the infection is performed under conditions that allow expression of the viral polypeptide to be detected.
The total volume of a virus preparation used to infect cells in culture is typically determined by the skilled artisan by taking into account such factors as the total number of cells to be infected, the particle concentration of the virus preparation, and the volume of the vessel in which the infection is performed. Preferably, the particle concentration of virus used to infect cells in the infection mixture is at least about 105 particles per ml, more preferably at least about I06 particles per ml, most preferably about 10'' particles per ml. The viral preparations typically are prepared under conditions favorable to stability of the virus. Conditions for infection and, optionally, culture after infection will depend on the particular virus and the viral or reporter gene used for detection. The term "culture" as used herein refers to any form of cell culture in which the minimum requirements are provided to the cells to enable continued survival for the period of interest. Thus, for example, culture can refer to preparation of a cell suspension in a suitable buffer, such as phosphate buffered saline or an incomplete growth medium, for a period of minutes or hours, or can refer cells adhering to culture dishes for minutes to days to weeks in the presence of a suitable complete growth medium. Typically, sufficient time in culture is provided for expression of the desired viral polypeptide, but preferably not enough time is provided for propagation of the infecting virus which results in further infection of cells. Thus, it is preferable that only "one round" of infection occur in these cells. In some embodiments, the length of time allowed "in culture" will be less than 1 hour to several hours. In other preferred embodiments, the length of time will be 1 to 5 days.
Typically, cells are infected under conditions favoring adsorption of the virus to the cells, although less optimal conditions can be used in some embodiments.
Typically, viruses are allowed to adsorb to cells for 1-12 hours. In some embodiments, the cells are infected in a concentrated suspension with concentrated virus, to enhance the rate of infection or the number of infected cells, then diluted to a concentration more favorable for cell or viral-growth. In some embodiments of the invention, it can be desirable to wash infected cells cultures to remove unabsorbed virus or components of the medium used for infection, or to expose the infected cells to media or growth conditions more favorable to their survival.
After sufficient time has elapsed to allow expression of the viral polypeptide, the cells are typically prepared as a suspension of single cells. When the cells are infected as adherent cells in tissue culture, the cultures are typically treated with a dissociating agent such as trypsin to detach the cells from the substratum. Mechanical means can also be used to detach cells, such as scraping. CeIIs are then collected by centrifugation and prepared in a buffer, such as incomplete or complete growth medium, for reaction with the detection reagents. Typically cells are "fixed" for immunostaining by any of a number of standard techniques. A
review of the commonly used fixation techniques is provided by Bauer and Jacobberger, etg s i~ dell Hiolaav 41:351-376 (1994)), all purposes. When the polypeptide is detected by its activity, fluorescent reagents can be introduced into cells to allow detection of the activity, such as a fluorescein labeled substrate for an enzyme.
Infected cell populations are then subjected to analysis by standard flow cytometry, such as by the methods disclosed by Shapiro, pTa ~ ~;La? Fi oa,L~rtomet~ , 3rd ed. , John Wiley and Sons (1994?, The term "FACS" is sometimes used to refer to flow cytometry, although cell sorting is not required to practice the instant invention. Typically, a minimum of about 10,000 events is acquired in the analysis.
Dead cells are typically excluded from the analysis either by forward/side scatter gating or PI labelling and setting of electronic windows on the PI negative fraction. A variety of commercial software packages are available to aid in preparation and analysis of the data, such as CellQuest'~".
The following example is intended to illustrate but not limit the invention in any way.
3 0 E7L8M~Ir$
In this example, ACNRH, a recombinant, replicative-defective adenovirus was titered by TCID~ and by the low particle number to cell number ratio flow ratio) method of the present invention. The exemplary virus used essentially comprised the adenovirus vector backbone disclosed by Wills et al. (~ns~r~.~ne Therabv Z:I91-197 (1995) ) with full-length retinoblastoma cDNA inserted into the vector.
BACKGROUND OF TFiE INVENTION
A particular challenge in the delivery of a gene by a viral vector for therapeutic purposes is the preparation and accurate characterization of clinical dosage forms. Total particle measurement can be made by such techniques as electron microscopy of viral preparations or measurement of total DNA by optical density at 260 nm of a sodium dodecyl sulfate (SDS) treated virus suspension. However, infectivity of a viral preparation, i.e., the number of infectious viral particles in a preparation of virus, is more challenging to accurately measure.
Traditionally, infectivity particles are measured in culture by a plaque-forming unit assay (pfu) that scores the number of viral plaques as a function of dilution. An alternative to the pfu assay is the tissue culture infective dose procedure (TCIDSo), which estimates infectivity as a function of intracellular staining for an antigen by direct immunofluorescence. The methods suffer from limitations including a high degree of inter-assay variability and are affected by such factors as virus replication status, vector characteristics, and virus-cell interactions.
More recently, flow cytometry or FACS (fluorescence-activated cell sorter) assays have been used to measure the number of infected cells in cell cultures infected at relatively high multiplicities of infection. For example, Saalmuller and Mettenleiter (J. Virol. Methods 44:99-108 (1993)) disclose the identification and quantitation of cells infected by recombinant pseudorabies virus mutants by the reaction of intracellular ~i-galactosidase expressed during infection with recombinant viruses with a fluorogenic substrate, followed by detection of positive cells in flow cytometry. Morris et al. (Virolow 197(1):339-48 (1993)) studied the process of productive and non-productive recombinant AcMNPV infection in cultured cells by immunostaining cells to detect the reporter CAT gene product.
The instant invention addresses the need for a more accurate method of quantitating infectious viral particles in a population.
SUMMARY OF THE INVENTION
The methods of the instant invention are based on the unexpected and surprising result that flow cytometry analysis of cells infected at a low virus to cell ratio yields a more accurate measurement of infectious virus titer than traditional titration methods.
One aspect of the invention is a method for determining the number of infectious virus particles in a population of virus particles comprising:
i) infecting cells in a cell population at a total particle to cell ratio of less than about 100:1 to about 0.1:1 to generate infected cells;
ii) reacting a polypeptide expressed by the virus in infected cells with an antibody labeled with a fluorescent tag, the antibody having specificity for a polypeptide expressed by the virus; and iii) measuring immunofluorescence in the product of step (ii) by flow cytometry to determine the number of infected cells, thereby determining the number of infectious virus particles.
When the virus is a recombinant virus, the viral polypeptide can be encoded by an exogenous gene, such as a reporter gene. In some embodiments of the invention, the exogenous gene is a tumor suppressor gene such as p53 or , retinoblastoma (RB). The recombinant virus can be replication competent or defective, deficient or incompetent.
In some embodiments of the invention, the virus is adenovirus. Thus, when the infected cells are cultured after infection to allow expression of a viral polypeptide, the viral polypeptide can be an adenovirus polypeptide such as hexon.
Typically the viral polypeptide is reacted with at least one antibody, although the antibody can be a mixture of antibodies. The antibody can be polyclonal or monoclonal.
In preferred embodiments of the invention,~the total particle to cell ratio is less than about 100:1, typically less than about 10:1, preferably less than about 5:1, more preferably less than about 1:1. In some embodiments, the ratio can be as low as about 0.1:1.
DETAILED DESCRIPTION
' The instant invention provided methods for quantitating infectious viral particles in a population of virus particles. The term "infectious" as used herein is intended to refer to the ability of a virus to enter cells and direct the synthesis of at least one polypeptide encoded by the virus. The ability to reproduce the viral nucleic acid is not required, but is included, by this definition.
Typically, not every virus particle in a preparation is infectious. For example, particles can be damaged in preparation of the virus, thereby not affecting total particle number but decreasing the number of particles capable of infection. Furthermore, empty capsids or instability of the virus extracellularly can also contribute to the decrease in infectivity. The range of non-infectious particles to infectious particles in viral preparations can range from 1:1 to greater than 100:1. However, even non-infectious viruses can cause cytological changes or damage to exposed cells.
Thus, it is advantageous to have an accurate measure of the number of infectious particles in a population so as to minimize the number of non-infectious viral particles to which cells are exposed.
Virtually any virus can be quantitated, or titered, by the methods of the instant invention, including DNA
viruses, RNA viruses, replication competent viruses, replication incompetent viruses, recombinant viruses, viruses carrying transgenes, etc. Preferably, the virus can infect cells in culture. Some example of viruses amenable to this technique include, but are not limited to, adenovirus, adeno-associated virus, retrovirus, herpes simplex virus, parvovirus, Epstein Barr virus, rhinotracheitis virus, parainfluenza virus, bovine diarrhea virus, sindbis virus, baculovirus, pseudorabies virus, varicella-zoster virus, cytomegalovirus, HIV, hepatitis A, B, and C viruses, and vaccinia.
In some embodiments of the invention, infectivity is measured by antibodies directed against a polypeptide expressed by the virus. The polypeptide may be a structural viral polypeptide, a regulatory polypeptide, a polypeptide such as a polymerase, and so on. In some embodiments of the invention, the polypeptide is preferably expressed by an exogenous gene incorporated into the virus, such as a reporter gene. Some examples of reporter genes include (3-galactosidase and chloramphenicol transacetylase (CAT). In further embodiments of the invention, the reporter gene is detected by antibodies directed against a product of the action of the reporter gene, such as the action of an enzyme on a substrate.
In other embodiments of the invention, the exogenous gene is a transgene intended for therapeutic use. Some examples include but are not limited to tumor suppressor genes, including p53 or retinoblastoma (RB); interleukins, including IL-2, IL-4, and IL-10; interferons, including alpha-, beta-, and gamma interferon; other cytokines; thymidine kinase; growth factors, including GCSF and growth hormone; Factor VIII; adenosine deaminase, and so on. Typically production of polypeptide encoded by a transgene will be measured by an antibody directed against the polypeptide.
Antibodies used for detection can be polyclonal, , monoclonal, or include mixtures of such antibodies.
Typically, the detection is done directly by using a , fluorescein-conjugated antibody directed against the viral polypeptide. However, indirect assays are also possible, in which the antibody directed against the viral polypeptide is then reacted with a fluorescein-labeled antibody. Any fluorescent label compatible with flow cytometry can be used.
To perform the assay of the invention, typically, the total number of virus particles in a viral preparation is 5 first measured by any of a number of traditional techniques.
For example, an aliquot of a virus preparation can be prepared in a buffer containing 0.1% sodium dodecyl sulfate (SDS), after which the optical absorbance is measured at 260 nm (Maizel et al. yirologv 36:115-125 (1968)). Total particle counts can also be obtained by preparing a sample of the viral preparation for electron microscopy, and simply counting the number of particles. A further technique for particle enumeration can include the use of anion-exchange chromatography (Huyghe et al. Oman Gene erarw 6:1403-1416 (1995)).
Cells are then infected with dilutions of the viral preparations at total particle number to cell number ratios no higher than about 100:1, typically less than about 10:1, preferably less than about 5:1, more preferably less than about 1:1. In some embodiments the ratio is as low as about 0.1:1. Typically, at least one infection will be performed, although in some embodiments at least two parallel infections are performed at different particle to cell ratios. The cells used are typically known to be sensitive to infection by the virus. It is not required that the cells support replication by the virus, but the infection is performed under conditions that allow expression of the viral polypeptide to be detected.
The total volume of a virus preparation used to infect cells in culture is typically determined by the skilled artisan by taking into account such factors as the total number of cells to be infected, the particle concentration of the virus preparation, and the volume of the vessel in which the infection is performed. Preferably, the particle concentration of virus used to infect cells in the infection mixture is at least about 105 particles per ml, more preferably at least about I06 particles per ml, most preferably about 10'' particles per ml. The viral preparations typically are prepared under conditions favorable to stability of the virus. Conditions for infection and, optionally, culture after infection will depend on the particular virus and the viral or reporter gene used for detection. The term "culture" as used herein refers to any form of cell culture in which the minimum requirements are provided to the cells to enable continued survival for the period of interest. Thus, for example, culture can refer to preparation of a cell suspension in a suitable buffer, such as phosphate buffered saline or an incomplete growth medium, for a period of minutes or hours, or can refer cells adhering to culture dishes for minutes to days to weeks in the presence of a suitable complete growth medium. Typically, sufficient time in culture is provided for expression of the desired viral polypeptide, but preferably not enough time is provided for propagation of the infecting virus which results in further infection of cells. Thus, it is preferable that only "one round" of infection occur in these cells. In some embodiments, the length of time allowed "in culture" will be less than 1 hour to several hours. In other preferred embodiments, the length of time will be 1 to 5 days.
Typically, cells are infected under conditions favoring adsorption of the virus to the cells, although less optimal conditions can be used in some embodiments.
Typically, viruses are allowed to adsorb to cells for 1-12 hours. In some embodiments, the cells are infected in a concentrated suspension with concentrated virus, to enhance the rate of infection or the number of infected cells, then diluted to a concentration more favorable for cell or viral-growth. In some embodiments of the invention, it can be desirable to wash infected cells cultures to remove unabsorbed virus or components of the medium used for infection, or to expose the infected cells to media or growth conditions more favorable to their survival.
After sufficient time has elapsed to allow expression of the viral polypeptide, the cells are typically prepared as a suspension of single cells. When the cells are infected as adherent cells in tissue culture, the cultures are typically treated with a dissociating agent such as trypsin to detach the cells from the substratum. Mechanical means can also be used to detach cells, such as scraping. CeIIs are then collected by centrifugation and prepared in a buffer, such as incomplete or complete growth medium, for reaction with the detection reagents. Typically cells are "fixed" for immunostaining by any of a number of standard techniques. A
review of the commonly used fixation techniques is provided by Bauer and Jacobberger, etg s i~ dell Hiolaav 41:351-376 (1994)), all purposes. When the polypeptide is detected by its activity, fluorescent reagents can be introduced into cells to allow detection of the activity, such as a fluorescein labeled substrate for an enzyme.
Infected cell populations are then subjected to analysis by standard flow cytometry, such as by the methods disclosed by Shapiro, pTa ~ ~;La? Fi oa,L~rtomet~ , 3rd ed. , John Wiley and Sons (1994?, The term "FACS" is sometimes used to refer to flow cytometry, although cell sorting is not required to practice the instant invention. Typically, a minimum of about 10,000 events is acquired in the analysis.
Dead cells are typically excluded from the analysis either by forward/side scatter gating or PI labelling and setting of electronic windows on the PI negative fraction. A variety of commercial software packages are available to aid in preparation and analysis of the data, such as CellQuest'~".
The following example is intended to illustrate but not limit the invention in any way.
3 0 E7L8M~Ir$
In this example, ACNRH, a recombinant, replicative-defective adenovirus was titered by TCID~ and by the low particle number to cell number ratio flow ratio) method of the present invention. The exemplary virus used essentially comprised the adenovirus vector backbone disclosed by Wills et al. (~ns~r~.~ne Therabv Z:I91-197 (1995) ) with full-length retinoblastoma cDNA inserted into the vector.
Total particle number was obtained by the "SDS/ODz6o"
method and anion exchange chromatography methods described above. In both assays the measured total particle concentration was 1.0 X 1012/ml.
Infectious particles were titered by TCIDSO assay as described by Huyghe et al. (Human Gene Theranv 6:1403-1416 ' (1995)). In brief, 293 cells were plated into a 96-well microtiter plate: 100,u1 of 5x105 cells/ml for each well in complete MEM (10% bovine calf serum; 1% glutamine) media (GIBCO BRL). In a separate plate, a 250-fcl aliquot of virus sample diluted 1:106 was added to the first column and was serially diluted two-fold across the plate. Seven rows were used for samples. One row was used for a negative control. A
100-~1 aliquot of each well was transferred to its identical position in the 293 seeded plate and allowed to incubate a 37°C in a humidified air/7% COZ incubator for 2 days. The media was then decanted by inversion and the cells fixed with 50% acetone/50% methanol. After washing with PBS, the fixed cells were incubated for 45 minutes with a FITC-labeled anti-Ad5 antibody (Chemicon International #5016) prepared according to the kit instructions. After washing with PBS, the plate was examined under a fluorescent microscope (490 mm excitation, 520 mm emission) and scored for the presence of label. The titer was determined using the Titerprint Analysis program (Lynn, Biotechnic~ues 12:880-881 (1992)).
The low ratio assay was performed as follows. 1 X
106 293 cells (human embryonic kidney cells, ATCC CRL 1573) were seeded per well on 4 6-well dishes. The final volume per well was 1 ml. After about 2 hr, the medium (Dulbecco's modified Eagle's medium (DME high glucose) containing 4500 mg/ml D-glucose, supplemented with 5% defined, iron-supplemented bovine calf serum, 2mM L-glutamine, and l mM
sodium pyruvate) in each well was aspirated and replaced with 1.1 ml of medium (without serum) containing diluted virus.
Adsorption was allowed to occur for 60 minutes, after which an additional 2m1 of virus-free medium was added to each well.
After about 42 hr, the infected cells cultures were processed for flow cytometry analysis.
method and anion exchange chromatography methods described above. In both assays the measured total particle concentration was 1.0 X 1012/ml.
Infectious particles were titered by TCIDSO assay as described by Huyghe et al. (Human Gene Theranv 6:1403-1416 ' (1995)). In brief, 293 cells were plated into a 96-well microtiter plate: 100,u1 of 5x105 cells/ml for each well in complete MEM (10% bovine calf serum; 1% glutamine) media (GIBCO BRL). In a separate plate, a 250-fcl aliquot of virus sample diluted 1:106 was added to the first column and was serially diluted two-fold across the plate. Seven rows were used for samples. One row was used for a negative control. A
100-~1 aliquot of each well was transferred to its identical position in the 293 seeded plate and allowed to incubate a 37°C in a humidified air/7% COZ incubator for 2 days. The media was then decanted by inversion and the cells fixed with 50% acetone/50% methanol. After washing with PBS, the fixed cells were incubated for 45 minutes with a FITC-labeled anti-Ad5 antibody (Chemicon International #5016) prepared according to the kit instructions. After washing with PBS, the plate was examined under a fluorescent microscope (490 mm excitation, 520 mm emission) and scored for the presence of label. The titer was determined using the Titerprint Analysis program (Lynn, Biotechnic~ues 12:880-881 (1992)).
The low ratio assay was performed as follows. 1 X
106 293 cells (human embryonic kidney cells, ATCC CRL 1573) were seeded per well on 4 6-well dishes. The final volume per well was 1 ml. After about 2 hr, the medium (Dulbecco's modified Eagle's medium (DME high glucose) containing 4500 mg/ml D-glucose, supplemented with 5% defined, iron-supplemented bovine calf serum, 2mM L-glutamine, and l mM
sodium pyruvate) in each well was aspirated and replaced with 1.1 ml of medium (without serum) containing diluted virus.
Adsorption was allowed to occur for 60 minutes, after which an additional 2m1 of virus-free medium was added to each well.
After about 42 hr, the infected cells cultures were processed for flow cytometry analysis.
The cells were detached from the plastic substratum with a trypsin-EDTA solution (GIHCO-BRL). Detached cells were collected from each well and centrifuged at about 200 x g for minutes at room temperature. The supernatants were removed 5 and the cells washed in Dulbecco's phosphate buffered saline (D-PBS) without calcium or magnesium salts. Pelleted cells were then resuspended in 2 ml cold acetone: methanol (1:1) fixative, then held on ice for 15 minutes. 7 ml D-PBS without calcium or magnesium salts was added to each tube, after which 10 the cells were resuspended in D-PBS with 1% (v/v) calf serum.
After repeating these last two steps, cells were resuspended in 501 D-PBS with 1% calf serum. 70 ul anti-adenovirus antibody conjugated with FITC (Chemicon #5016) in 2.0 ml D-PBS
was added to each tube. The samples were incubated at 37°C
for about 50 minutes. The samples were then transferred to flow cytometry analysis tubes, diluted slightly with 0.5 ml D-PBS, and analyzed by flow cytometry. A Becton-Dickinson FACScanT" Flow Cytometer System, PN 34011570, 12-00189-01 with FACStation (MAC QUADR.A 650 computer, monitor, and printer) was used with CellQuest~ Software.
The results are shown in Table 1. By the traditional TCIDSO assay, the total particle number to infectious unit ratio was 63:1. As is evident in the table, as the total particle number to cell number ratio decreased, the calculated total particle number: infectious unit ratio also decreased to as low as 12:1, thereby providing a value for infectious titer that was about 5-fold higher than the traditional assay. Thus, this low ratio assay provides an unexpectedly better (i.e. much more accurate) enumeration of 3o the number of infectious particles in a viral preparation than traditional methods for titration. The consequences of such accurate measurements proved by the instant invention are especially important in calculating the effective doses of recombinant viruses for therapeutic use.
M
..~ a.
: ., , o x o .-. .. r.
~ ' ~ ~ .oz R ~ ~~ .~
o.
e.
..
..
R
o a a ~
E o o c o ~::
a X.. K_ X,~ a ~
..
h ~ j 8.
c ... E%
o o o ~c , a c.i v +I +I +I
: ~ C
U
c oho ~ ~ E" o C . ri oo "a Z
e a a m U
d ..
r, 0 0 a o o a o a ~,.a o00 00 000 i! ~! X ~S
ft St i!
X ~ ' ~O O M M
00 M !Z
N
Ci ~~ M M h O~
'" ~~ O~
N
R
U
.~ o00 00 ~
N
M
V MMlt' -,, V7hh ..
r.
L' oa ~ E
a coo coo ~oc o _ X X X ,~ x X
x X X
~n cn ~ ~o ~'~ t ' ~ o ~O ~ ~
~ .-n "
~ M
O
~ w ~ ~
~L
a~ M D O
o U o 0 0 r U
H
O
w d O
O~ O0 CQ 00 h h ~
C4 "' M O
~."
~U
E
After repeating these last two steps, cells were resuspended in 501 D-PBS with 1% calf serum. 70 ul anti-adenovirus antibody conjugated with FITC (Chemicon #5016) in 2.0 ml D-PBS
was added to each tube. The samples were incubated at 37°C
for about 50 minutes. The samples were then transferred to flow cytometry analysis tubes, diluted slightly with 0.5 ml D-PBS, and analyzed by flow cytometry. A Becton-Dickinson FACScanT" Flow Cytometer System, PN 34011570, 12-00189-01 with FACStation (MAC QUADR.A 650 computer, monitor, and printer) was used with CellQuest~ Software.
The results are shown in Table 1. By the traditional TCIDSO assay, the total particle number to infectious unit ratio was 63:1. As is evident in the table, as the total particle number to cell number ratio decreased, the calculated total particle number: infectious unit ratio also decreased to as low as 12:1, thereby providing a value for infectious titer that was about 5-fold higher than the traditional assay. Thus, this low ratio assay provides an unexpectedly better (i.e. much more accurate) enumeration of 3o the number of infectious particles in a viral preparation than traditional methods for titration. The consequences of such accurate measurements proved by the instant invention are especially important in calculating the effective doses of recombinant viruses for therapeutic use.
M
..~ a.
: ., , o x o .-. .. r.
~ ' ~ ~ .oz R ~ ~~ .~
o.
e.
..
..
R
o a a ~
E o o c o ~::
a X.. K_ X,~ a ~
..
h ~ j 8.
c ... E%
o o o ~c , a c.i v +I +I +I
: ~ C
U
c oho ~ ~ E" o C . ri oo "a Z
e a a m U
d ..
r, 0 0 a o o a o a ~,.a o00 00 000 i! ~! X ~S
ft St i!
X ~ ' ~O O M M
00 M !Z
N
Ci ~~ M M h O~
'" ~~ O~
N
R
U
.~ o00 00 ~
N
M
V MMlt' -,, V7hh ..
r.
L' oa ~ E
a coo coo ~oc o _ X X X ,~ x X
x X X
~n cn ~ ~o ~'~ t ' ~ o ~O ~ ~
~ .-n "
~ M
O
~ w ~ ~
~L
a~ M D O
o U o 0 0 r U
H
O
w d O
O~ O0 CQ 00 h h ~
C4 "' M O
~."
~U
E
Claims (16)
1. A method for determining the number of infectious virus particles in a population of virus particles comprising:
i) infecting cells in a cell population at a total particle number to cell number ratio of less than about 100:1 to about 0.1:1 to generate infected cells;
ii) reacting a polypeptide expressed by the virus in infected cells with an antibody labeled with a fluorescent tag, the antibody having specificity for a polypeptide expressed by the virus; and iii) measuring immunofluorescence in the product of step (ii) by flow cytometry to determine the number of infected cells, thereby determining the number of infectious virus particles.
i) infecting cells in a cell population at a total particle number to cell number ratio of less than about 100:1 to about 0.1:1 to generate infected cells;
ii) reacting a polypeptide expressed by the virus in infected cells with an antibody labeled with a fluorescent tag, the antibody having specificity for a polypeptide expressed by the virus; and iii) measuring immunofluorescence in the product of step (ii) by flow cytometry to determine the number of infected cells, thereby determining the number of infectious virus particles.
2. The method of claim 1, wherein the virus is adenovirus.
3. The method of claim 2, wherein the viral polypeptide is hexon.
4. The method of claim 1, wherein the cells are cultured after infection to allow expression of the viral polypeptide.
5. The method of claim 1, wherein the virus is a recombinant virus.
6. The method of claim 5, wherein the viral polypeptide is encoded by an exogenous gene.
7. The method of claim 6, wherein the exogenous gene is a reporter gene.
8. The method of claim 6, wherein the exogenous gene is p53.
9. The method of claim 6, wherein the exogenous gene is retinoblastoma.
10. The method of claim 1, wherein the antibody is a mixture of antibodies.
11. The method of claim 1, wherein the antibody is polyclonal.
12. The method of claim 1, wherein the antibody is monoclonal.
13. The method of claim 5, wherein the recombinant virus is replication defective.
14. The method of claim 1, wherein the ratio is less than about 10:1 to about 0.1:1.
15. The method of claim 1, wherein the ratio is less than about 5:1 to about 0.1:1.
16. The method of claim 1, wherein the ratio is about 0.1:1.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US67848596A | 1996-07-09 | 1996-07-09 | |
US08/678,485 | 1996-07-09 | ||
CA002259549A CA2259549C (en) | 1996-07-09 | 1997-07-07 | Method for measuring viral infectivity |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002259549A Division CA2259549C (en) | 1996-07-09 | 1997-07-07 | Method for measuring viral infectivity |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2531850A1 true CA2531850A1 (en) | 1998-01-15 |
Family
ID=36121813
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002531850A Abandoned CA2531850A1 (en) | 1996-07-09 | 1997-07-07 | Method for measuring viral infectivity |
Country Status (1)
Country | Link |
---|---|
CA (1) | CA2531850A1 (en) |
-
1997
- 1997-07-07 CA CA002531850A patent/CA2531850A1/en not_active Abandoned
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6248514B1 (en) | Methods for measuring viral infectivity | |
Newcomb et al. | Cell-free assembly of the herpes simplex virus capsid | |
Preston et al. | Identification and characterization of a herpes simplex virus gene product required for encapsidation of virus DNA | |
Baldick Jr et al. | Human cytomegalovirus tegument protein pp71 (ppUL82) enhances the infectivity of viral DNA and accelerates the infectious cycle | |
Marschall et al. | Recombinant green fluorescent protein-expressing human cytomegalovirus as a tool for screening antiviral agents | |
Duus et al. | Wild-type Kaposi's sarcoma-associated herpesvirus isolated from the oropharynx of immune-competent individuals has tropism for cultured oral epithelial cells | |
Blair et al. | Restricted replication of human adenovirus type 5 in mouse cell lines | |
Broder et al. | Expression of foreign genes in cultured human primary macrophages using recombinant vaccinia virus vectors | |
Cepko et al. | Analysis of Ad5 Hexon and 100K is mutants using conformation-specific monoclonal antibodies | |
EP3325970B1 (en) | High throughput methods for virus quantification | |
Grosche et al. | Herpes simplex virus type 1 propagation, titration and single-step growth curves | |
Weaver et al. | Evaluation of adenoviral vectors by flow cytometry | |
Courtney et al. | Synthesis of virus-specific polypeptides by temperature-sensitive mutants of herpes simplex virus type | |
EP1023467B1 (en) | Method for measuring viral infectivity | |
Carpenter et al. | Egress of light particles among filopodia on the surface of varicella-zoster virus-infected cells | |
CA2259549C (en) | Method for measuring viral infectivity | |
Klupp et al. | Identification, subviral localization, and functional characterization of the pseudorabies virus UL17 protein | |
CA2531850A1 (en) | Method for measuring viral infectivity | |
Wunner et al. | Protein synthesis in BHK21 cells infected with vesicular stomatitis virus: I. ts mutants of the indiana serotype | |
MXPA99000396A (en) | Method for measuring inefficiency vi | |
Liu et al. | Serum proteomics with SELDI‐TOF‐MS in congenital human cytomegalovirus hepatitis | |
Kawai et al. | A sensitive bioassay system for detecting defective interfering particles of rabies virus | |
Park et al. | Rapid titer assay of adenovirus containing green fluorescent protein gene using flow cytometric analysis | |
Goldman et al. | Cellular and C-type viral factors in infections by polyoma virus hr-t mutants | |
Jenson | Epstein‐Barr virus |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Dead |